Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...

The following is a summary of "Prognostic value of non-invasive right ventricle-pulmonary artery coupling in patients with ...

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration ...

[9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled Surveillance of North American Pulmonary Hypertension (SNAP). The goal of the ...

Pulmonary hypertension is classified into 5 groups based on its cause, according to the American Lung Association: This group ...

A combination treatment may improve survival in patients with both pulmonary hypertension and pulmonary fibrosis, a study ...

Gradient Denervation Technologies, which is based in Paris, France, announced that the company’s pulmonary artery denervation ...

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Unfortunately, Epoprostenol, Tadallafil, Sotatercept, treprostinyl inhalants used for group 3 pulmonary hypertension, which are still not introduced in Korea, and Riosiguad of group 4 pulmonary ...

Synhale has acquired telaglenastat, and is planning a Phase 2 clinical trial testing the therapy in patients with pulmonary ...